Filtered By:
Cancer: Ovarian Cancer
Drug: Tamoxifen
This page shows you your search results in order of date.
Order by Relevance | Date
Total 52 results found since Jan 2013.
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
CONCLUSION: Adding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy.PMID:37607321 | DOI:10.1200/JCO.23.00557
Source: Clinical Breast Cancer - August 22, 2023 Category: Cancer & Oncology Authors: Soo Yeon Baek Woo Chul Noh Sei-Hyun Ahn Hyun-Ah Kim Jai Min Ryu Seung Il Kim Eun-Gyeong Lee Seock-Ah Im Yongsik Jung Min Ho Park Kyong Hwa Park Su Hwan Kang Joon Jeong Eunhwa Park Sung Yong Kim Min Hyuk Lee Lee Su Kim Woosung Lim Seonok Kim Hee Jeong Kim Source Type: research
Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study
CONCLUSION: Oral MCT was found to be an effective and well-tolerated regime with good symptomatic control and low-moderate toxicity profile in patients with relapsed and metastatic ovarian cancer. However, 22% of patients showed grade-III/IV thrombocytopenia.PMID:37530237 | DOI:10.4103/ijc.IJC_143_20
Source: Cancer Control - August 2, 2023 Category: Cancer & Oncology Authors: Kamlesh K Harsh Shankar L Jakhar Guncha Maheshwari Rajkumar Nirban Pramila Kumari Surender K Beniwal Neeti Sharma Harvindra S Kumar Source Type: research
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting
CONCLUSION: In a real-world setting, treatment options for premenopausal patients who are candidates for HT and OFS should take risk status into account. Therefore, every effort should be made to maintain patient adherence to treatment in order to manage toxicities and improve outcomes.PMID:37507257 | DOI:10.1016/j.clbc.2023.06.013
Source: Clinical Genitourinary Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Raffaella D'Onofrio Claudia Omarini Angela Toss Isabella Sperduti Federico Piacentini Monica Barbolini Laura Cortesi Elena Barbieri Elisa Pettorelli Chiara Chiavelli Massimo Dominici Luca Moscetti Source Type: research
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Curr Treat Options Oncol. 2023 Apr 15. doi: 10.1007/s11864-023-01082-3. Online ahead of print.ABSTRACTFor high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer (HR + /HER2 - EBC), short- and long-term recurrence risks remain substantial despite local control with surgery and radiation and systemic treatment with chemotherapy and endocrine therapy (ET). Recent trials have provided new strategies for reducing recurrence. The monarchE trial demonstrated that adding 2 years of adjuvant abemaciclib to ET improves invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS). In the Oly...
Source: Cancer Control - April 15, 2023 Category: Cancer & Oncology Authors: Jamie O Brett Erica L Mayer Source Type: research
Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group
Bull Cancer. 2023 Mar 27:S0007-4551(23)00141-8. doi: 10.1016/j.bulcan.2023.03.003. Online ahead of print.ABSTRACTLow-grade endometrial stromal sarcoma (LG-ESS) accounts for approximately 15% of all uterine sarcomas. Median age of patients is around 50 years and half of the patients are premenopausal. In all, 60% of cases present with FIGO stage I disease. Preoperatively radiologic findings of ESS are not specific. Pathological diagnosis remains essential. This review aimed to present the French guidelines for low grade ESS treatment within the Groupe sarcome français - Groupe d'étude des tumeurs osseuse (GSF-GETO)/NETSAR...
Source: Bulletin du Cancer - March 29, 2023 Category: Cancer & Oncology Authors: Coriolan Lebreton Pierre Meeus Catherine Genestie Sabrina Croce Fr édéric Guyon Carmen Llacer Moscardo Sophie Taieb Jean-Yves Blay Sylvie Bonvalot Emmanuelle Bompas Christine Chevreau Fabrice L écuru L éa Rossi Florence Joly Maria Rios Lo ïc Chaignea Source Type: research
